Investigation of PTEN Promoter Methylation in Ameloblastoma

Overview

Journal Med Oral Patol Oral Cir Bucal

Specialty Dentistry

Date 2020 Mar 6

PMID 32134893

Citations 6

Authors

P Lapthanasupkul

B Klongnoi

A Mutirangura

N Kitkumthorn

Affiliations

Soon will be listed here.

Abstract

Background: Phosphatase and tensin homolog (PTEN) acts as a tumor suppressor gene. Inactivation of PTEN has been reported in various types of cancers. PTEN promoter methylation possibly underlies PTEN inactivation, which results in tumorigenesis. The aim of this study was to investigate whether PTEN promoter methylation contributes to PTEN inactivation in ameloblastoma and its associated protein expression.

Material And Methods: In total, 20 fresh-frozen ameloblastoma samples were evaluated for PTEN promoter methylation using methylation-specific polymerase chain reaction (MS-PCR). A subset of 10 paraffin-embedded ameloblastoma samples was examined for PTEN expression through immunohistochemistry. Four primary cultured ameloblastoma cells were investigated for PTEN promoter methylation and PTEN transcriptional expression via reverse transcription PCR.

Results: PTEN promoter methylation was detected in 65% (13/20) of the ameloblastoma samples. Of 10 ameloblastoma samples, 4 exhibited reduced PTEN expression. Of 5 samples with methylated PTEN, 3 (60%) were associated with loss of PTEN expression. However, PTEN expression was detected in 4 (80%) of 5 samples with unmethylated PTEN. In addition, 3 (75%) of 4 primary ameloblastoma cell cultures exhibited an inverse correlation between PTEN promoter methylation and PTEN transcription level.

Conclusions: PTEN promoter methylation is found in a number of ameloblastomas but not significantly correlated with loss of PTEN expression. Genetic or epigenetic mechanisms other than PTEN promoter methylation may contribute to PTEN inactivation in ameloblastoma tumor cells.

Citing Articles

Mutation of PTEN: Loss and Likelihood of Being a Non-responder to Trastuzumab in a Sample of Iraqi Her2+ Breast Cancer Patients.

Hammadi A, Ali S Cureus. 2024; 16(2):e54765.

PMID: 38524002 PMC: 10961105. DOI: 10.7759/cureus.54765.

Bioactive PI3-kinase/Akt/mTOR Inhibitors in Targeted Lung Cancer Therapy.

Ghareghomi S, Atabaki V, Abdollahzadeh N, Ahmadian S, Hafez Ghoran S Adv Pharm Bull. 2023; 13(1):24-35.

PMID: 36721812 PMC: 9871280. DOI: 10.34172/apb.2023.003.

Systemic Deficiency of PTEN Accelerates Breast Cancer Growth and Metastasis.

Chen J, Sun J, Wang Q, Du Y, Cheng J, Yi J Front Oncol. 2022; 12:825484.

PMID: 35372075 PMC: 8971716. DOI: 10.3389/fonc.2022.825484.

Expression of DNMTs and H3K9ac in Ameloblastoma and Ameloblastic Carcinoma.

Amaral-Silva G, Melo de Lima Morais T, Wagner V, Martins M, Fregnani E, Soares F Front Oral Health. 2022; 2:751162.

PMID: 35048062 PMC: 8757744. DOI: 10.3389/froh.2021.751162.

Downregulation of MicroRNA-130a Inhibits Oral Squamous Cell Carcinoma Proliferation and Metastasis via the Hippo-YAP Pathway.

Peng Y, Hu S, Zhang K, Wang Y, Rouzi M, Zhou D Cancer Manag Res. 2021; 13:4829-4840.

PMID: 34168502 PMC: 8216666. DOI: 10.2147/CMAR.S287575.

References

Scheper M, Chaisuparat R, Nikitakis N, Sauk J . Expression and alterations of the PTEN / AKT / mTOR pathway in ameloblastomas. Oral Dis. 2008; 14(6):561-8. DOI: 10.1111/j.1601-0825.2007.01421.x. View

Petrovic I, Migliacci J, Ganly I, Patel S, Xu B, Ghossein R . Ameloblastomas of the mandible and maxilla. Ear Nose Throat J. 2018; 97(7):E26-E32. PMC: 6104513. DOI: 10.1177/014556131809700704. View

Puerta-Garcia E, Canadas-Garre M, Angel Calleja-Hernandez M . Molecular biomarkers in colorectal carcinoma. Pharmacogenomics. 2015; 16(10):1189-222. DOI: 10.2217/PGS.15.63. View

Bhusan Kar I, Subramanyam R, Mishra N, Singh A . Ameloblastic carcinoma: A clinicopathologic dilemma - Report of two cases with total review of literature from 1984 to 2012. Ann Maxillofac Surg. 2014; 4(1):70-7. PMC: 4073467. DOI: 10.4103/2231-0746.133070. View

Huhns M, Salem T, Schneider B, Krohn M, Linnebacher M, Prall F . PTEN mutation, loss of heterozygosity, promoter methylation and expression in colorectal carcinoma: two hits on the gene?. Oncol Rep. 2014; 31(5):2236-44. DOI: 10.3892/or.2014.3097. View

Cully M, You H, Levine A, Mak T . Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis. Nat Rev Cancer. 2006; 6(3):184-92. DOI: 10.1038/nrc1819. View

Lu Y, Cheng F, Teng L . The association between phosphatase and tensin homolog hypermethylation and patients with breast cancer, a meta-analysis and literature review. Sci Rep. 2016; 6:32723. PMC: 5020353. DOI: 10.1038/srep32723. View

Turker M . Gene silencing in mammalian cells and the spread of DNA methylation. Oncogene. 2002; 21(35):5388-93. DOI: 10.1038/sj.onc.1205599. View

Zysman M, Chapman W, Bapat B . Considerations when analyzing the methylation status of PTEN tumor suppressor gene. Am J Pathol. 2002; 160(3):795-800. PMC: 1867163. DOI: 10.1016/S0002-9440(10)64902-4. View

10.

Baeza N, Weller M, Yonekawa Y, Kleihues P, Ohgaki H . PTEN methylation and expression in glioblastomas. Acta Neuropathol. 2003; 106(5):479-85. DOI: 10.1007/s00401-003-0748-4. View

11.

Dahia P, Fitzgerald M, Zhang X, Marsh D, Zheng Z, Pietsch T . A highly conserved processed PTEN pseudogene is located on chromosome band 9p21. Oncogene. 1998; 16(18):2403-6. DOI: 10.1038/sj.onc.1201762. View

12.

Soria J, Lee H, Lee J, Wang L, Issa J, Kemp B . Lack of PTEN expression in non-small cell lung cancer could be related to promoter methylation. Clin Cancer Res. 2002; 8(5):1178-84. View

13.

Xu W, Yang Z, Lu N . Roles of PTEN (Phosphatase and Tensin Homolog) in gastric cancer development and progression. Asian Pac J Cancer Prev. 2014; 15(1):17-24. DOI: 10.7314/apjcp.2014.15.1.17. View

14.

Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang S . PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science. 1997; 275(5308):1943-7. DOI: 10.1126/science.275.5308.1943. View

15.

Khan S, Kumagai T, Vora J, Bose N, Sehgal I, Koeffler P . PTEN promoter is methylated in a proportion of invasive breast cancers. Int J Cancer. 2004; 112(3):407-10. DOI: 10.1002/ijc.20447. View

16.

Bouras E, Karakioulaki M, Bougioukas K, Aivaliotis M, Tzimagiorgis G, Chourdakis M . Gene promoter methylation and cancer: An umbrella review. Gene. 2019; 710:333-340. DOI: 10.1016/j.gene.2019.06.023. View

17.

Marsit C, Zheng S, Aldape K, Hinds P, Nelson H, Wiencke J . PTEN expression in non-small-cell lung cancer: evaluating its relation to tumor characteristics, allelic loss, and epigenetic alteration. Hum Pathol. 2005; 36(7):768-76. DOI: 10.1016/j.humpath.2005.05.006. View

18.

Nodit L, Barnes L, Childers E, Finkelstein S, Swalsky P, Hunt J . Allelic loss of tumor suppressor genes in ameloblastic tumors. Mod Pathol. 2004; 17(9):1062-7. DOI: 10.1038/modpathol.3800147. View

19.

Narayan B, Urs A, Augustine J, Singh H, Polipalli S, Kumar S . Genetic alteration of Exon 5 of the PTEN gene in Indian patients with ameloblastoma. Oral Surg Oral Med Oral Pathol Oral Radiol. 2019; 127(3):225-230. DOI: 10.1016/j.oooo.2018.11.011. View

20.

Akca H, Demiray A, Aslan M, Acikbas I, Tokgun O . Tumour suppressor PTEN enhanced enzyme activity of GPx, SOD and catalase by suppression of PI3K/AKT pathway in non-small cell lung cancer cell lines. J Enzyme Inhib Med Chem. 2012; 28(3):539-44. DOI: 10.3109/14756366.2011.654114. View